DDA Platform Develops High Quality Bioanalysis Services for to Guarantee the Safety of Cosmetics Products

January 24 13:06 2022
DDA platform announced the release of its flagship bioanalysis services to develop better cosmetic formulations and products.

New York, USA – January 24, 2022 – DDA platform, the mature division of Creative Bioarray, is dedicated to providing integrated drug discovery services to pharma, biotechnology companies, and academic institutions around the world. With the most highly experienced and specialized staff in pharmacology, DDA platform is capable to provide customers with unique, high-quality, distinctive, and tailored integrated drug discovery services. Recently, it announced the release of its flagship bioanalysis services to develop better cosmetic formulations and products.

As an industry leader in bioanalytical services for the cosmetic industry, the researchers at the DDA platform have more than 10 years of experience in cell testing. The team has been dedicated to developing the highly specialized analytical expertise, deep insights and innovative technologies required for the success of accelerated cosmetic trials. With strong expertise in numerous in vitro and ex vivo models and skin physiology, DDA platform is capable of designing tailored protocols and assays.

DDA platform is committed to the safety and effectiveness of its products by providing personalized service through smooth communication with customers, maximizing the quality of the work chain, and executing and sending reports quickly in response at the end. DDA platform conducts comprehensive in vitro and ex vivo testing for compound efficacy determination and cosmetic claim confirmation.

DDA platform provides in vitro 3D skin tissue models and assays for the assessment of cosmetic efficacy and supports the enhancement of skin barrier function and hydration. In vitro testing of skincare products needs to be carried out with great precision and requires a combination of professional scientific skills, excellent technical knowledge and attention to detail. Drawing on extensive scientific experience and regulatory expertise, the DDA platform offers OECD 428 compliant in vitro dermal absorption studies. A team of professionals will work with clients to create custom programs using human or rat skin, whether finished products or cosmetic ingredients.

The DDA platform provides a three-layer in vitro skin sensitization test based on the AOP principle and is an alternative to the currently popular in vivo method. The use of this set of analyses allows for a weight-of-evidence approach to hazard assessment of potential skin sensitizers without the use of laboratory animals. Based on expertise in cell and tissue engineering, Creative Bioarray develops in vitro or ex vivo models suitable for analyzing the interaction between the microbiome and skin. These models can assess the effects of compounds or formulations on bacterial development and bacterial responses to the skin.

“Our platform utilizes the best screening equipment and cell models, as well as the latest innovations in drug discovery to deliver first-class results to our clients.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Our professionals are always committed to helping our customers accelerate life science research, solve complex analytical challenges, and increase laboratory productivity.”

About DDA platform

As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerate drug development and improve research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://dda.creative-bioarray.com